Related Funds
Fund Name | Location |
Bain Capital Private Equity | England, London, United Kingdom |
Brandshoots Ventures | India, Kolkata, West Bengal |
Capital One Growth Ventures | California, San Francisco, United States |
DiGAME | Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates |
Fidelity National Title Insurance | California, Santa Rosa, United States |
Gfund | Beijing, Beijing, China |
Global Investment House | Al Kuwayt, Kuwait, Safat |
ICT Group N.V. | Barendrecht, The Netherlands, Zuid-Holland |
Innovus | South Africa, Stellenbosch, Western Cape |
Jollibee Food | Pasig, Philippines, Rizal |
MetLife Digital Accelerator powered by Techstars | Cary, North Carolina, United States |
NetSol Technologies | Calabasas, California, United States |
Parrot | France, Ile-de-France, Paris |
Shanghai Momoying Investment Development Center (LP) | - |
Solent Local Enterprise Partnership | Hampshire, Portsmouth, United Kingdom |
Southern Oregon Angel Investors Network | Medford, Oregon, United States |
The Vinik Family Foundation | - |
Zhiying Capital | China, Shanghai |
Zuma Ventures | California, Santa Monica, United States |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Cardurion Pharmaceuticals | $260M | 16 Jul 2024 | Boston, Massachusetts, United States | ||
AltruBio | $225M | 21 May 2024 | California, United States | ||
Avenzo Therapeutics | $150M | 26 Mar 2024 | San Diego, California, United States | ||
Instylla | $30M | 15 Aug 2023 | Massachusetts, United States | ||
Eccogene | $27M | 12 Jun 2023 | Shanghai, China | ||
Ensoma | $50M | 16 May 2023 | Boston, Massachusetts, United States | ||
Rejoni | $25M | 07 Dec 2022 | Bedford, Massachusetts, United States | ||
Rgenta Therapeutics | $52M | 29 Nov 2022 | Cambridge, Massachusetts, United States | ||
OncoMyx Therapeutics | $50M | 09 Dec 2021 | Phoenix, Arizona, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Cardurion Pharmaceuticals | $260M | 16 Jul 2024 | Boston, Massachusetts, United States | ||
AltruBio | $225M | 21 May 2024 | California, United States | ||
Avenzo Therapeutics | $150M | 26 Mar 2024 | San Diego, California, United States | ||
Instylla | $30M | 15 Aug 2023 | Massachusetts, United States | ||
Eccogene | $27M | 12 Jun 2023 | Shanghai, China | ||
Ensoma | $50M | 16 May 2023 | Boston, Massachusetts, United States | ||
Rejoni | $25M | 07 Dec 2022 | Bedford, Massachusetts, United States | ||
Rgenta Therapeutics | $52M | 29 Nov 2022 | Cambridge, Massachusetts, United States | ||
OncoMyx Therapeutics | $50M | 09 Dec 2021 | Phoenix, Arizona, United States |